Effects of Adrenaline Infiltration on Surgical Field of View in Endoscopic Sinus Surgery

Sponsor
Stanford University (Other)
Overall Status
Completed
CT.gov ID
NCT05867342
Collaborator
(none)
40
1
1
15.3
2.6

Study Details

Study Description

Brief Summary

In endoscopic sinus surgery a clear surgical field of view is a very important aspect for good surgical outcome. This study is to evaluate the preoperative preparation to acquire best surgical field of view by comparing between the use of topical adrenaline and the use of combination of topical adrenaline with infiltration of 1% lidocaine with adrenaline in patients scheduled for endoscopic sinus surgery for rhinosinusitis.

Condition or Disease Intervention/Treatment Phase
Phase 4

Study Design

Study Type:
Interventional
Actual Enrollment :
40 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Effects of Adrenaline Infiltration on Surgical Field of View in Endoscopic Sinus Surgery
Actual Study Start Date :
May 12, 2017
Actual Primary Completion Date :
Aug 22, 2018
Actual Study Completion Date :
Aug 22, 2018

Arms and Interventions

Arm Intervention/Treatment
Experimental: Endoscopic sinus surgery

Participants receive topical 1:1000 epinephrine plus saline in one nostril, and topical 1:1000 epinephrine plus infiltration of 1% lidocaine with 1:100,000 epinephrine in the other nostril, during endoscopic visualization while undergoing Endoscopic sinus surgery (ESS).

Drug: Epinephrin
Topical application of 2 pieces of Epinephrin (1:1,000)-soaked cottonoid in nasal cavity
Other Names:
  • Adrenaline
  • Drug: 1% lidocaine with epinephrin 1:100,000
    4 ml intranasal infiltration of 1% lidocaine with epinephrine (1:100,000) at 2 sites (2 ml infiltration at each site)

    Drug: Saline
    4 ml intranasal infiltration of saline at 2 sites (2 ml infiltration at each site)

    Outcome Measures

    Primary Outcome Measures

    1. Surgical field grading score [Up to 30 minutes to assess]

      The video recording of the endoscopic sinus surgery of the participant will be graded by another otolaryngology specialist and will be graded according to Wormald Surgical Field Grading Scale. Scores range from 0 (no bleeding) to 10 (severe bleeding with nasal cavity filling rapidly).

    Secondary Outcome Measures

    1. Postoperative bloody discharge grading score [1 week after the surgery (up to 2 minutes to complete assessment)]

      Grading of postoperative bloody discharge assessed by patient using the postoperative bleeding questionaire. Scores range from 0 (no bleeding) to 5 (continuous heavy bleeding necessitating medical care).

    2. Number of days with postoperative bloody nasal discharge [1 week after the surgery (up to 2 minutes to complete assessment)]

      Days with postoperative bloody nasal discharge assessed by patient using the postoperative bleeding questionaire.

    3. Number of patients with excessive fresh bleeding [1 week after the surgery (up to 2 minutes to complete assessment)]

      Assessed by patient using the postoperative bleeding questionaire.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 80 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Diagnosed with recurrent acute or chronic rhinosinusitis recalcitrant to medical treatment and scheduled for endoscopic sinus surgery
    Exclusion Criteria:
    • Patients who have asymetrical disease on the two sides (Lund Mackay score difference more than 2)

    • Patients who have endoscopic sinus surgery for treatment of tumor or disease other than sinusitis

    • Patients with underlying uncontrolled hypertension

    • Patients with bleeding disorder or are unable to discontinue antiplatelet or anticoagulant before the surgery

    • Patients who are allergic to adrenaline or to xylocaine

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Stanford Stanford California United States 94304

    Sponsors and Collaborators

    • Stanford University

    Investigators

    • Study Director: Peter H Hwang, MD, Stanford University
    • Principal Investigator: Navarat Tangbumrungtham, MD, Stanford University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Stanford University
    ClinicalTrials.gov Identifier:
    NCT05867342
    Other Study ID Numbers:
    • 40274
    First Posted:
    May 22, 2023
    Last Update Posted:
    May 22, 2023
    Last Verified:
    May 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    Yes
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of May 22, 2023